文献速递神经免疫认知障碍与痴呆

AQP4与MOG抗体检测对特发性横贯性脊髓炎流行病学的影响

Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology.
PubMed 文献 · Neurology · 2019-06-24

该观察性研究在Olmsted县回顾性识别2003–2016年符合2002年标准的特发性横贯性脊髓炎(ITM)患者,检测AQP4-IgG和MOG-IgG并将血清阳性者重新分类为疾病相关TM。3例血清阳性(AQP4-IgG 2例,MOG-IgG 1例)占 incident 14%、prevalent 12%,重新分类后ITM incidence 为8.6/1,000,000、prevalence 为7.9/100,000,仍高于既往报道。

要点

  • 检测AQP4/MOG抗体可使部分ITM重新分类为疾病相关TM。
  • 血清阳性者占特发性LETM的50%(3/6)。
  • 重新分类后ITM incidence 8.6/1,000,000、prevalence 7.9/100,000。

核心结论

  • AQP4-IgG和MOG-IgG检测使ITM的incidence和prevalence轻度降低,但仍高于既往报道。
  • 建议在未来TM诊断标准修订中纳入这些生物标志物。

研究设计与样本

  • 观察性研究,回顾性识别Olmsted县2003年1月1日至2016年12月31日incident及2016年12月31日prevalent的ITM病例。
  • ITM按2002年Transverse Myelitis Consortium Working Group诊断标准定义。
  • 24例患者(incident 22,prevalent 17)初始符合2002 ITM标准,其中长节段横贯性脊髓炎(LETM)6例。
  • 22/24(92%)检测AQP4-IgG,21/24(88%)检测MOG-IgG。

主要发现

  • 3例血清阳性(AQP4-IgG 2例,MOG-IgG 1例)被重新分类为疾病相关TM,占incident 14%、prevalent 12%。
  • AQP4-IgG和MOG-IgG血清阳性病例占特发性LETM的50%(3/6)。
  • 重新分类后最终ITM incidence为8.6/1,000,000,prevalence为7.9/100,000。
  • 3例ITM(14%)在研究期间后续满足多发性硬化诊断标准。

关键数值与推荐

  • ITM定义采用2002年Transverse Myelitis Consortium Working Group诊断标准。
  • 血清阳性重新分类标准:AQP4-IgG或MOG-IgG阳性即归为疾病相关TM。

临床怎么用

  • 对符合2002年ITM标准的患者应检测AQP4-IgG和MOG-IgG以重新分类。
  • 血清阳性者按疾病相关TM管理,而非特发性TM。

局限性

  • 回顾性观察性研究,部分患者血清未检测(AQP4-IgG 2例未测,MOG-IgG 3例未测)。
  • Olmsted县人群85%为白人,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Diagnostic criteria from 2002 classify transverse myelitis (TM) as idiopathic or disease associated but predate the discovery of aquaporin-4 (AQP4)-immunoglobulin G (IgG) and myelin oligodendrocyte glycoprotein (MOG)-IgG, which associate with TM. Prior incidence estimates of idiopathic TM (ITM) range from 1 to 6.2 per 1 million. We sought to determine whether the population-based incidence and prevalence of ITM were reduced by testing patients with ITM for AQP4/MOG-IgG and reclassifying seropositive cases as having disease-associated TM. METHODS: For this observational study, we retrospectively identified all cases of incident (January 1, 2003-December 31, 2016) and prevalent (December 31, 2016) ITM in Olmsted County (85% white) by using the Rochester Epidemiology Project medical records linkage system. ITM was defined by the 2002 Transverse MyelitisConsortium Working Group diagnostic criteria. Available sera were tested for AQP4-IgG and MOG-IgG. RESULTS: Twenty-four patients (incident 22, prevalent 17) initially met 2002 ITM criteria (longitudinally extensive TM [LETM] 6). Sera were tested for AQP4-IgG in 22 of 24 (92%) and MOG-IgG in 21 of 24 (88%). Three seropositive cases (AQP4-IgG 2, MOG-IgG 1) were identified and reclassified as having disease-associated TM, accounting for 14% of total incident and 12% of total prevalent cases. AQP4-IgG and MOG-IgG seropositive cases represented 50% (3 of 6) of idiopathic LETM. After reclassification of seropositive patients, the final ITM incidence was 8.6 per 1,000,000 and prevalence was 7.9 per 100,000. Three cases of ITM (14%) subsequently fulfilled multiple sclerosis criteria within the study period. CONCLUSIONS: The availability of AQP4-IgG and MOG-IgG modestly reduced ITM incidence and prevalence, which remained higher than previously reported in this predominantly white population. Incorporation of these biomarkers into future revisions of TM diagnostic criteria should be considered.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Sechi E, Shosha E, Williams JP, et al. Aquaporin-4 and MOG autoantibody discovery in idiopathic transverse myelitis epidemiology. Neurology. 2019. PMID: 31235660. doi:10.1212/WNL.0000000000007828

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。